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In the field of contrast-enhanced ultrasonography (US), contrast agents are classified as either 
first- or second-generation agents depending on the gas within the microbubbles. In the case of 
first-generation contrast agents, a high-mechanical-index technique is used and only intermittent 
scanning is possible due to the early destruction of the microbubbles during the scanning. 
The use of second-generation contrast agents in a low-mechanical-index technique enables 
continuous scanning. Besides the detection and characterization of focal liver lesions, contrast-
enhanced US is helpful in the monitoring of radiofrequency ablation therapy and in the targeting 
step of an US-guided biopsy. Recently, there has been a demand for new criteria to evaluate the 
treatment response obtained using anti-angiogenic agents because morphologic criteria alone 
may not reflect the treatment response of the tumor and contrast-enhanced US can provide 
quantitative markers of tissue perfusion. In spite of the concerns related to its cost-effectiveness, 
contrast-enhanced US has the potential to be more widely used as a complimentary tool or to 
substitute the current imaging modalities in some occasions.
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Introduction
For ultrasonography (US), contrast agents were first introduced in 1996 and have since been used 
mainly for echocardiography, vascular US, Doppler US, and abdominal US in Europe and Asia. 
Although contrast-enhanced US (CEUS) has several advantages over the contrast-enhanced computed 
tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMR), such as no radiation, 
no harmful effects to the kidney or thyroid, easy accessibility, and comparable comfort during use with 
patients [1], it has not been widely used in abdominal applications. In the case of first-generation 
US contrast agents, early breakdown of microbubbles limits the contrast effect during continuous 
scanning. With the development of second-generation US contrast agents in 2001 and the advances 
of the contrast-specific mode with a low-mechanical index (MI) technique in US machines, a real-time 
evaluation has become possible, resulting in an increasing interest in US contrast agents and CEUS. In 
this review, we discuss the principles and types of US contrast agents and the clinical application of 
CEUS with a focus on abdominal imaging.
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US Contrast Agents
General Principles
Conventional grayscale US is used to obtain anatomical information, 
and Doppler US can be performed if information about blood flow 
is needed. However, Doppler US can depict blood flow information 
only in relatively large vessels due to a low signal-to-noise ratio, and 
cannot evaluate the blood flow of microvessels and tissue perfusion 
[2]. US contrast agents overcome this limitation by their physical 
properties. US contrast agents consist of microbubbles containing 
air or various gases within a shell. When a US contrast agent is 
administered into the vasculature, it enhances the backscatter of 
the ultrasound waves by resonance within sonic windows [3]. This 
results in a marked amplification of the signals from the blood flow 
and provides additional information about the microvasculature [2]. 
By using a US contrast agent and the contrast-specific mode of the 
US machine, dynamic CEUS images can be obtained in the same 
manner as CECT or CEMR images, but with different enhancement 
patterns that are not always comparable with those of CECT 
or CEMR. This is attributed to the fact that a US contrast agent 
is retained only within the blood vessels (known as blood-pool 
contrast agent), whereas a contrast agent of computed tomography 
(CT) and magnetic resonance imaging (MRI) moves into the 
extracellular space after administration until the concentration of 
the contrast agent is balanced between the intravascular space and 
the extracellular space [4].
The MI is defined as the peak rarefactional (or negative) pressure 
divided by the square root of the ultrasound frequency. Most 
commercially available US machines display the MI values on 
their screens, and an MI value of 0.1-2.0 (mostly more than 1.0) 
is usually used for conventional grayscale US [2,5]. The MI value 
is related to the insonation power of the microbubble within the 
ultrasound field. At a very low MI, microbubbles stay static and only 
play a role in the scattering of the US beam. As the MI increases, 
microtubules oscillate at their resonance frequency linearly (MI < 
approximately 0.2) or nonlinearly (approximately 0.2 < MI < 0.5). In 
cases where the MI is more than 0.5, microbubbles oscillate strongly 
and expand beyond their limit, resulting in a disruption of the 
bubbles [2,5]. CEUS images can be created from either the signals 
of the nonlinear oscillation of microbubbles or the signals from the 
microbubble destruction [2].
To detect specific signals from a small amount of US contrast 
agent, the use of the contrast-specific US mode is essential 
[6]. Linear signals at a very low MI are generated from both 
the US contrast agent and the tissue; these signals are too 
similar to discriminate even with the most-recently developed 
US technology. Nonlinear signals generated by the US contrast 
agent can be separately detected by the CEUS-specific mode, 
and then, the corresponding CEUS images can be generated. 
Unfortunately, nonlinear signals are also generated by the tissue, 
and US equipment and technology that can discriminate between 
these signals and the US contrast agent signals are still under 
investigation. Because nonlinear signals from the tissue and the 
US equipment are proportional to the MI, the second-generation 
US contrast agents, which are used in the case of low MI, offer an 
advantage by decreasing non-US contrast agent signals [6,7].
Generations and Types
The generation of US contrast agents is categorized according to 
the type of gas within the microbubble shells. The first-generation 
US contrast agent, Levovist (Bayer Schering Pharma, Berlin, 
Germany), was introduced in 1996 and consisted of air within a 
shell of galactose microparticles (99.9%)/palmic acid (0.1%). After 
intravenous administration, it distributed itself within the blood 
pool within a few minutes, and about 2 minutes after its injection, 
the late phase or the liver/spleen-specific phase could be obtained 
[4,8,9]. The mechanism for the specific uptake of Levovist in the 
liver and spleen is not yet completely understood, but it is thought 
to be similar to the 99mTc-colloid uptake in scintigraphy or the super 
paramagnetic iron-oxide uptake in the reticuloendothelial system in 
liver MRI [10]. The mean size of Levovist microbubbles is 2-5 μm, 
and 97% of them are less than 7 μm in size. This size is sufficient for 
them to pass through the microcapillaries of the lung, which have a 
mean diameter of 7 μm without embolisms, and to travel to the left 
ventricle of the heart or liver for the generation of CEUS images [3,8]. 
The air within the Levovist contrast is made up of small molecules 
and can easily diffuse through the microbubble shell into the 
blood. Furthermore, because of the high solubility of air in blood, 
the diffused air outside the microbubbles can easily dissolve into 
the blood more quickly than preferred [3]. To improve the stability 
of the microbubbles, there was an attempt to make a shell with a 
polymer-based material, but it was not successfully commercialized 
due to poor image quality [3]. However, another effort to stabilize 
microbubbles by replacing air with a more inert and slowly diffusing 
gas such as sulfur hexafluoride or perfluorobutane was successful, 
and second-generation US contrast agents such as SonoVue (Bracco, 
Milano, Italy), Definity (marketed in North America as Luminity by 
Lantheus Medical Imaging, North Billerica, MA, USA), Optison (GE 
Healthcare, Princeton, NJ, USA), and Sonazoid (GE Healthcare, Oslo, 
Norway) were introduced. Definity consists of octafluoropropane 
gas within a lipid shell, and Optison consists of octafluoropropane 
within an albumin shell. Both have been approved only for cardiac 
applications [3,6]. SonoVue consists of sulfur hexafluoride (SF6) 
within a phospholipid shell. SF6 is an inert molecule that does not 
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interact with any other molecule in the body [2]. After destruction 
of the microbubble, SF6 gas is excreted only through the lungs 
without any excretion through the kidney or the liver. The shell 
consists of a monolayer of an amphiphilic phospholipid. As the outer 
side of the shell, which is in contact with blood, has hydrophilic 
properties and the inner side has hydrophobic properties, the shell 
can stably contain SF6 gas [2]. SonoVue was initially approved 
for the evaluation of the heart and macrovascular (cerebral and 
peripheral arteries, and the portal vein) and microvascular structures 
(characterization of focal lesions in the liver and the breast) [6]. 
However, its cardiac application has been temporarily suspended 
by the European Medicines Agency (EMEA) [11]. Sonazoid consists 
of perfluorobutane within a hydrogenated egg phosphatidylserine 
(HEPS) shell. In contrast to SonoVue, Sonazoid can be used to obtain 
both vascular-phase and Kupffer-phase images, which are usually 
obtained 10-15 minutes after the administration of the US contrast 
agent. In the Kupffer phase, microbubbles are trapped by the 
Kupffer cells and lead to a homogeneous enhancement in normal-
functioning liver parenchyma [3]. Sonazoid has only been approved 
in Japan and Korea for the evaluation of focal liver lesions.
A high MI (MI > 0.7) was used for the first-generation US 
contrast agents. With the high-MI technique, CEUS images are 
created using signals from microbubble destruction; hence, the 
continuous acquisition of CEUS images is impossible. As a result, 
only intermittent scanning can be performed for a few seconds, 
and during the CEUS examination, images are recorded frame by 
frame. With some intervals, CEUS images can be obtained again if 
the undestroyed US contrast agent is replenished. Recorded images 
can be reviewed frame by frame after the examination without any 
time constraint [8,12]. In comparison, the low-MI technique (MI < 
0.3) can be applied to second-generation US contrast agents, and 
continuous, real-time scanning is possible in this case [8].
Safety Considerations
A US contrast agent is excreted via the lung after the destruction 
of the microbubbles; hence, it is not nephrotoxic. Further, it does 
not contain iodine, thereby not having any effect on the thyroid 
functions. Although the US contrast agent is very safe, it can be 
regarded as a foreign material by the immune system; therefore, a 
hypersensitivity reaction is possible [1]. The incidence of a severe 
hypersensitivity reaction was reported in about 0.002% in large-
scale abdominal application studies [13,14]. The overall reported 
incidence of the hypersensitivity reaction was less than that 
occurring with the use of an iodine contrast agent in CT and was 
similar to that of the use of a gadolinium chelate contrast agent in 
MRI [1].
Contraindications of SonoVue are a recent acute coronary 
syndrome or clinically unstable ischemic cardiac disease, right-to-
left shunts, severe pulmonary hypertension, uncontrolled systemic 
hypertension, and adult respiratory distress syndrome [11,15]. 
Recently, the use of SonoVue in echocardiography has been 
temporarily suspended because of possible severe hypertension, 
bradycardia, cardiac arrest, and acute myocardial infarction, which 
were mostly reported during echocardiography as an idiosyncratic 
hypersensitivity reaction [11]. Sonazoid is contraindicated in patients 
with right-to-left shunts, severe pulmonary hypertension, and adult 
respiratory distress syndrome. It should not be used or, if it must 
be used, it should be used with extreme caution in patients with 
egg allergies, because the Sonazoid shell is made of HEPS sodium 
[15]. Because the safety of SonoVue and Sonazoid has not been 
evaluated in pregnant women, in women who are breast-feeding, or 
in patients who are younger than 18 years of age, both US contrast 
agents should be avoided in these patients.
Although not yet proven in vivo with human subjects, there is 
a possibility that microbubbles with insonation can cause harmful 
effects to cells or tissue, such as microvascular rupture, hemolysis of 
red blood cells, increased heating around the US contrast agent, and 
killing of phagocytic cells that have engulfed the US contrast agent 
[14]. The European Federation of Societies of Ultrasound in Medicine 
and Biology (EFSUMB) guidelines have recommended caution as 
damage to the microvessel can be clinically harmful to the eye or 
the brain [16]. According to previous in vivo animal studies [14], an 
MI value of more than 0.4 rapidly accelerates this harmful biological 
effect; hence, MI values should be maintained as low as possible 
during the entire examination.
Clinical Application of CEUS
Guidelines
The need for CEUS guidelines increased in the early 2000s and 
discussion on this matter began at the EUROSON Congress in 2003. 
The first version of a CEUS guideline was published in January 
2004 [4]. This guide dealt with the general considerations for CEUS, 
including an overview of US contrast agents, imaging techniques, 
and safety considerations. In terms of clinical applications, the first 
EFSUMB guideline focused on the evaluation of focal liver lesions 
[4]. The updated version, which was published in 2008, included 
the monitoring of focal liver lesions after ablative treatment and 
applications to other organs, such as applications to the kidney 
and pancreas, transcranial US, and US for blunt abdominal trauma 
[6]. A recent guideline update dealt with nonhepatic applications 
of CEUS, such as applications to the gastrointestinal tract, spleen, 
vesicoureteral reflux, scrotum, lung and pleural lesions, breasts and 
inflammatory joints [16]. In contrast to its use in Europe, CEUS has 
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not been widely used in North America. The main reason for this 
is that the second-generation US contrast agents, which can be 
used for applications other than cardiac indications, have not yet 
been approved by regulatory agencies such as the United States 
Food and Drug Administration (USFDA). Recently, the revised 
American Association for the Study of Liver Disease (AASLD) practice 
guideline for the management of hepatocellular carcinoma (HCC) 
removed CEUS from its diagnostic flow algorithm because the 
second-generation US contrast agents used for liver imaging are 
not yet approved in the United States and because intrahepatic 
cholangiocarcinoma (ICC) might be falsely diagnosed as HCC on 
CEUS [17]. However, because there is criticism about the updated 
AASLD guideline, and phase III trials of liver CEUS are ongoing 
[18,19], CEUS might be included in future diagnostic guidelines with 
broader applications.
Evaluation of Focal Liver Lesions
Dynamic contrast enhanced images of the liver can be obtained with 
US contrast agents similar to CECT and CEMR. The arterial phase 
starts about 10-20 seconds and lasts for 30-45 seconds after the 
administration of a US contrast agent. Vascularity of the focal lesion 
can be evaluated during the arterial phase. The portal venous phase 
(PVP) starts at 30-45 seconds and continues for 2-3 minutes 
[16]. On the portal-venous-phase images, the degree of washout 
between the focal liver lesion and the adjacent liver parenchyma 
can be compared [4]. “Washout” is defined as the transition of 
hyperenhancement or isoenhancement to hypoenhancement 
as compared to the adjacent normal liver parenchyma [16]. In 
comparison to SonoVue of which only 7.3% is phagocytized by 
Kupffer cells, 99% of injected Sonazoid is phagocytized by Kupffer 
cells, and thus, a Kupffer-phase image can be additionally obtained 
about 10-15 minutes after the administration of Sonazoid [20]. The 
equilibrium phase of CECT or CEMR does not exist on CEUS. This 
is because the US contrast agent is a pure intravascular contrast 
agent, and the concentration equilibrium of the US contrast agent 
between the extracellular space and the intravascular space cannot 
be achieved [6].
Detection of Focal Liver Lesions
The sensitivity for detecting liver metastasis has been reported 
to be about 87%-91% even with Levovist [21]. However, there 
were limitations for the evaluation of the whole liver because 
of insufficient examination time due to the instability of the US 
contrast agents, a result of microbubble destruction occurring during 
examinations. The sensitivity was reported to be about 79%-100% 
with second-generation US contrast agents, which is significantly 
higher than that of conventional grayscale US and comparable 
with that of CT [21-24]. For a metastasis smaller than 1 cm, the 
sensitivity improved markedly from 29.1%-35% to 63.3%-76.6% 
upon the use of US contrast agents as compared to that in the 
case of conventional grayscale US; this sensitivity improvement 
was comparable with that of CT [24]. Recently, preoperative or 
postoperative chemotherapy has been frequently performed in 
patients with colorectal cancer in order to decrease the tumor 
burden or to kill the possible remnant cancer cells. Chemotherapy 
can insult the liver parenchyma and lead to fat depositions, 
resulting in a texture change of the liver and decrease in the 
contrast resolution between the metastasis and the adjacent liver 
parenchyma. As the metastasis presents with hypoenhancement as 
compared to the adjacent liver parenchyma during the PVP or the 
late phase, CEUS can improve the diagnostic sensitivity for detecting 
metastasis in these patients from 63.2% to 79.5%, and thereby 
enable more accurate surgical planning [25]. Further, intraoperative 
CEUS can help to accurately diagnose the retracted liver metastasis 
after chemotherapy, and its diagnostic performance is comparable 
with that of MRI [26,27]. However, there have also been conflicting 
results that show multiple detector computed tomography (MDCT) 
having better sensitivity than CEUS, and surgical plans have also 
been changed in some patients because of a metastasis that was 
not detected on CEUS but was detected on CT [26,28]. Hence, CEUS 
cannot yet solely replace MDCT in the evaluation of liver metastasis, 
and further studies on the diagnostic performance of CEUS with 
second-generation US contrast agents and a state-of-the-art CEUS-
specific mode are warranted.
Differential Diagnosis of Focal Liver Lesions
On CEUS, most benign lesions show hyperenhancement or 
isoenhancement as compared to adjacent normal liver parenchyma 
in the PVP (Fig. 1), whereas malignant lesions usually present as 
hypoechoic in the PVP or the delayed phase (Fig. 2) [6]. According to 
the meta-analysis studies, CEUS can accurately differentiate between 
benign and malignant focal liver lesions with a sensitivity of 93% 
and a specificity of 90%, and the diagnostic performance of CEUS 
is similar to that of CECT and CEMR [29,30]. In some reports, CEUS 
has been reported to provide a conclusive diagnosis when focal liver 
lesions were incidentally found on conventional grayscale US [31,32]. 
Furthermore, CEUS could improve the diagnostic accuracy from 
42%-44% to 89%-92% for lesions that have been found to be 
inconclusive on CECT and improve the diagnostic confidence level 
[32]. Hence, CEUS can be used as a second-line diagnostic tool for 
the evaluation of incidentally found indeterminate focal liver lesions 
on conventional grayscale US or contrast-enhanced CT.
Most lesions that are less than 1 cm in size in patients with an 
extrahepatic malignancy are too small to characterize on CECT. 
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The differential diagnosis of these lesions between metastases and 
benign lesions such as hepatic cysts is important for treatment 
planning. In general, conventional grayscale US is used as a first-line 
tool for differential diagnosis because it can accurately differentiate 
cysts from solid lesions. However, some lesions are also inconclusive 
on conventional grayscale US, and additional assessment with MRI 
or intraoperative US may be needed for the differential diagnosis. 
In a previous study, CEUS was used to successfully diagnose 98.5% 
of the inconclusive cases on both CECT and conventional grayscale 
US and led to changes in the treatment plans in 11.6% of these 
patients [33].
Conventional grayscale US has been used as a screening tool 
in patients with chronic liver disease due to its noninvasiveness, 
relatively low cost, lack of radiation exposure, and easy accessibility. 
However, the reported diagnostic accuracy for HCC was not 
considered sufficient, particularly for small lesions, even though 
early detection is a major prognostic factor for improving patient 
survival [34]. Furthermore, nodules other than HCC, such as 
regenerative nodules or dysplastic nodules, commonly accompany in 
a cirrhotic liver, and as HCC can present with nodules with various 
echogenicities, conventional grayscale US is limited in the detection 
and differentiation of HCC in patients with chronic liver disease [35]. 
For the differential diagnosis of the detected nodules, understanding 
the vascularity within a lesion is crucial, and usually CECT or CEMR 
A B
Fig. 1. A 64-year-old male with focal nodular hyperplasia. 
A. A T1-weighted magnetic resonance image showed a hypervascular nodular lesion in the right lobe of the liver (arrow). B. In the 
hepatobiliary phase, the lesion showed a higher signal intensity (arrow) than the adjacent liver parenchyma. C. In the arterial phase of 
contrast-enhanced ultrasonography (US), the lesion showed hypervascularity (arrowheads). D. In the portal venous phase, the lesion showed 
iso-echogenicity (arrowhead) relative to the adjacent liver. The lesion was confirmed as focal nodular hyperplasia by an US-guided biopsy.
C D
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tumor vascularity, the combination of the evaluation techniques 
improved the sensitivity for differentiating HCC from benign nodules 
in patients with liver cirrhosis, by decreasing the false-negative rate 
[34,40].
Intraoperative CEUS also improved the diagnostic accuracy of 
HCC. According to a previous report, intraoperative CEUS with 
Sonazoid could newly detect about 9.4% of HCC, and the surgical 
extent was changed in 42.9% of patients in whom HCC was newly 
detected during CEUS [41].
Portal vein thrombosis is frequently observed in patients with 
liver cirrhosis or HCC. In these patients, differentiation between 
tumor thrombosis and bland thrombosis is critical to determine 
treatment plans or to predict prognosis because tumor thrombosis 
is one of the common excluding reasons for not performing surgery, 
transplantation, or radiofrequency ablation (RFA) [42]. Furthermore, 
even if there is portal vein thrombosis without definite evidence of a 
mass-forming lesion in the liver on conventional US, a careful further 
examination is needed to check whether there is an undetected 
infiltrative HCC. Although Doppler US was used to diagnose tumor 
thrombosis in previous research, the sensitivity and the diagnostic 
accuracy were only about 20% and 50%, respectively [42]. On 
CEUS, tumor thrombosis can be diagnosed when there is an 
enhancement in the arterial phase, in which the sensitivity and the 
diagnostic accuracy can be improved to 88%-100% and 92.5%, 
respectively (Fig. 3) [35,42,43].
The diagnostic performance of CEUS was found to be significantly 
lower in patients with chronic hepatitis than in patients without 
is used as a secondary diagnostic tool after the detection of nodules 
in a cirrhotic liver. CEUS has also been used to evaluate lesion 
vascularity with a diagnostic accuracy similar to that of CECT [34]. 
Small HCCs, those less than 2 cm in size, were accurately diagnosed 
using CEUS with a sensitivity of 81% and a specificity of 86% 
[36]. HCC usually appears as a hypervascular lesion in the arterial 
phase and as a hypovascular lesion in the PVP or the delayed phase 
[6,35]. However, another problem is that enhancement patterns 
vary depending on the degree of differentiation. In previous studies, 
about 13% of HCC did not appear as hypervascular lesions as 
compared to the adjacent liver parenchyma in the arterial phase, 
and well differentiated or poorly differentiated HCC tended to 
appear as lesions other than the hypervascular lesions in the arterial 
phase. Furthermore, 9% of HCC did not show hypovascular lesions 
in the delayed phase and 78% of them were well differentiated 
HCC [37,38]. In short, moderately differentiated HCC tends to show 
a typical enhancement pattern, which is arterial enhancement and 
washout in the delayed phase, whereas well or poorly differentiated 
HCC frequently presents with an atypical enhancement pattern. 
Hence, careful assessment is needed to evaluate nodular lesions in 
patients with chronic liver disease [34].
In the comparison of imaging modalities, gadolinium ethoxybenzyl 
diethylenetriaminepentaacetic acid (Gd-EOB-DTPA [86%])-enhanced 
MRI showed better sensitivity than both contrast-enhanced CT (74%) 
and CEUS (72%), and when Gd-EOB-DTPA and CEUS were used 
together in the evaluation, the sensitivity improved up to 90% [39]. 
In addition, when CEUS and MDCT were used together to assess 
Fig. 2. A 64-year-old female with gallbladder carcinoma. 
A. In the portal venous phase of computed tomography, a hypo-attenuating lesion was noted in segment 7 of the liver (arrow). B. In the 
portal venous phase of the ultrasonography (US), the lesion showed hypo-echogenicity compared with the adjacent liver. The lesion was 
confirmed as a metastasis by a US-guided biopsy (arrow).
A B
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chronic liver disease [31,44]. This might be due to technical 
difficulties such as limited time for the whole liver assessment; 
limited sonic window due to anatomical changes such as hypotrophy 
of the right hepatic lobe; heterogeneous enhancement of the liver 
parenchyma due to the arterioportal shunt, which is often found in 
cirrhotic livers; and the relatively less extensive enhancement of the 
liver parenchyma as compared to the normal liver [6,35].
In the cost-effectiveness analysis of CEUS as a surveillance tool 
for HCC in patients with compensated hepatitis C virus-related liver 
cirrhosis, it was shown that CEUS surveillance using Sonazoid is a 
cost-effective strategy when the annual incidence of HCC is more 
than 2% and the sensitivity of CEUS for detecting HCC is more 
than 80% [45]. However, there is still not enough evidence for 
using CEUS as a screening tool, and CEUS may rather be used as a 
problem-solving method, particularly for nodules sized between 1 
and 2 cm [38,46].
Sonazoid introduced an additional advantage to CEUS by 
providing the Kupffer phase, which usually starts from 10-15 
minutes to 120 minutes after Sonazoid administration [47]. In the 
Kupffer phase, areas of normal functional Kupffer cells showed 
enhancement due to microbubbles being phagocytized by Kupffer 
cells, with specificity being improved as compared to conventional 
B-mode US from 89.2%-94.9% to 97.8%-98.2% in HCC 
detection [48]. The histologically more advanced HCC might appear 
as more hypoechoic than the adjacent liver parenchyma, which was 
comparable to the signal intensity difference in the hepatobiliary 
phase of Gd-EOB-DTPA-enhanced MRI [49,50]. Another advantage 
of Sonazoid-enhanced US is the defect reperfusion image in which 
both Kupffer-phase and arterial phase images can be evaluated 
simultaneously and with the same slice by reinjection of Sonazoid 
during the Kupffer phase [51]. According to a previous study, 
Sonazoid-enhanced US showed better diagnostic accuracy (95%) 
than CECT (82%) in the depiction of malignant hepatic lesions by 
using the defect reperfusion technique [52].
A B
Fig. 3. A 57-year-old female with malignant portal vein thrombosis. 
Computed tomography (A) and conventional ultrasonography (US) 
(B) showed tumor thrombosis (arrows) in the right and the main 
portal veins. C. On contrast-enhanced US, contrast enhancement 
suggesting tumor thrombosis was clearly noted within the 
thrombosis (arrowheads).
C
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Differential diagnosis between ICC and HCC in patients with 
chronic liver disease or liver cirrhosis is a controversial issue, and 
the recently updated AASLD guideline removes CEUS from the 
diagnostic procedure for HCC due to the possibility of the false- 
positive diagnosis of HCC in patients with ICC [17]. This decision 
by AASLD is based on an article that reported that 47.6% of ICC 
showed homogeneous intense enhancement in the arterial phase 
and washout in the delayed phase on CEUS, findings that were 
not distinguishable from HCC [53,54]. However, the following 
studies showed that the enhancement pattern was somewhat 
different between the two tumors because HCC is more likely to 
appear as homogeneous or heterogeneous hyperenhancement, 
whereas ICC often presents with peripheral rim-like enhancement 
or heterogeneous hypoenhancement in the arterial phase [55]. In 
the quantitative analysis with the time-intensity curve, ICC showed 
a more rapid and marked washout than HCC, although there 
was significant overlap between the two [56,57]. Because ICC 
develops in patients with liver cirrhosis or chronic hepatitis, and 
ICC smaller than 3 cm is more likely to appear as homogeneous 
hyperenhancement in the arterial phase with delayed washout, a 
finding also typical of HCC [55,58], careful interpretation of CEUS 
is needed in smaller nodules that develop in patients with liver 
cirrhosis or chronic hepatitis.
CEUS-Guided Procedures
If the lesion was not clearly delineated on conventional US, but 
was well visualized on CT or MRI, a biopsy can be performed after 
the administration of a US contrast agent (Fig. 4). In lesions that 
have a large proportion of central necrosis, it may turn out that 
tissue is obtained only from the necrotic portion of the liver on 
a conventional grayscale US-guided biopsy, making a pathologic 
diagnosis impossible and requiring a re-biopsy. On CEUS, the viable 
portion of the tumor can be differentiated from the necrotic portion 
by the presence or absence of enhancement, and a targeted biopsy 
A B
Fig. 4. A 64-year-old female with metastatic neuroendocrine 
carcinoma in the liver. 
A. The hepatobiliary phase of magnetic resonance showed a low 
signal intensity lesion in segment 4 (S4) of the liver (arrow). B. 
On conventional ultrasonography (US), the lesion was not clearly 
detected. C. After contrast enhancement, a low echoic lesion (arrow) 
was detected on S4 of the liver. US-guided biopsy was performed 
after lesion localization on contrast-enhanced US, and the lesion 
was confirmed as metastatic neuroendocrine carcinoma.
C
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can be performed at the viable portion of the tumor (Fig. 5).
During the RFA of inconspicuous lesions, fusion imaging with 
conventional grayscale US and CECT or CEMR can be used for RFA 
guiding. If the lesion is inconspicuous even with fusion imaging with 
conventional grayscale US, CEUS can be additionally used. According 
to a previous study, about 83% of HCC, which was inconspicuous on 
fusion imaging with conventional grayscale US, was well visualized 
after the contrast enhancement of US [59]. After RFA of the hepatic 
tumor, it is essential to evaluate the treatment response. Although 
CECT has been used for this purpose, there are several limitations, 
including possible harmful effects of radiation and the iodinated 
contrast agent, and an inaccurate assessment of the ablated margin. 
Furthermore, even though a residual viable tumor is detected on 
CECT, it is sometimes difficult to visualize and target the residual 
viable tumor on conventional grayscale US, particularly immediately 
after RFA [60]. Because CEUS can overcome these disadvantages, 
it can be used in the evaluation of the post-RFA response. For 
hypervascular lesions such as HCC, if the intratumoral vascularity, 
which was noted before treatment, disappeared on postprocedural 
CECT or CEUS, complete ablation of the tumor can be confirmed. 
For hypovascular lesions such as metastasis, successful ablation can 
be confirmed if the ablated zone does not show enhancement on 
CECT or CEUS, including the target lesion. It is important to secure a 
sufficient safety margin (>5 mm) to ablate satellite nodules around 
the main lesion and to prevent marginal recurrence. According 
to previous studies, the diagnostic accuracy of CEUS (93.8%-
100%) for the evaluation of the RFA treatment response with either 
SonoVue or Sonazoid was comparable with CECT or CEMR [47,60-
63]. The optimal time to assess the treatment response to RFA is 3 
hours after the procedure because the treated tumor margin is the 
most clearly perceived at this time [60]. Uniform rim enhancement 
can be seen up to 30 days after RFA, and this rim enhancement 
should not be misdiagnosed as marginal tumor recurrence [6]. 
Efforts have also been made to evaluate the treatment response 
A B
Fig. 5. A 76-year-old male with gallbladder carcinoma.
A. On computed tomography, a nodular lesion with central necrosis 
was noted on S4 of the liver (arrow). B. Ultrasonography (US)-guided 
biopsy was performed, and the pathologic result was total necrotic 
tissue. C. On contrast-enhanced US, the lesion showed a peripheral 
enhancing area (arrow), which suggested a viable portion, with 
central necrosis (arrowheads). A re-biopsy was performed targeting 
the viable peripheral portion, and the final pathologic diagnosis was 
metastasis.
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after trans-arterial chemoembolization (TACE) with CEUS. Although 
CEUS could detect residual intratumoral vascularity after TACE in 
previous studies, it is not feasible to use it as an evaluation tool 
after TACE because of the difficulty in evaluating multiple lesions, 
deeply located lesions, and poorly enhancing or diffusely growing 
lesions [63,64].
Quantitative Analysis
The most widely used assessment tool for treatment response is the 
response evaluation criteria in solid tumors (RECIST); these criteria 
are based on the serial change in the lesion size. Recently, anti-
angiogenic agents have been developed for several diseases, and 
concerns have been raised that an evaluation of only size is not 
sufficient for an accurate assessment. Hence, the recently suggested 
modified RECIST (mRECIST) and Choi criteria aim to include not 
only the size changes but also the changes in enhancing patterns 
within the tumor on contrast-enhanced images [65,66]. Besides 
studies on conventional CECT or CEMR, perfusion studies have been 
performed to predict the treatment response as early as possible, 
but radiation exposure during perfusion CT and a lack of standard 
protocols or the technical complexity of perfusion MRI limit the 
generalized use of perfusion imaging for tumor assessment. CEUS 
can potentially assess the response by a perfusion study because 
it is technically easy and sufficiently feasible for daily practice 
and there is no harm from radiation or from the contrast agent. 
Furthermore, several quantitative parameters such as the degree 
of peak enhancement, mean transit time, and time to peak (TTP) 
enhancement can be obtained by analyzing the time-intensity curve 
[16]. In previous studies, quantitative parameters calculated from 
CEUS showed a moderate correlation with that of CECT [67,68]. 
Further, peak enhancement, regional blood volume, regional blood 
flow, and rise time have been reported to be significantly higher in 
the case of benign focal liver lesions than in the case of malignant 
lesions [69,70]. Perfusion CEUS can also predict the microvessel 
A B
Fig. 6. A 49-year-old female with vulvar cancer and acute 
pyelonephritis.
A. In the renal parenchyma phase of computed tomography (CT), 
a wedge-shaped hypo-attenuating lesion was newly detected in 
the mid pole of the left kidney (arrows). To exclude metastasis, 
an ultrasonography (US)-guided biopsy was planned. B. On con-
ventional US, the lesion, which was noted on CT, was not detected. 
C. After contrast enhancement, a poorly enhancing wedge-shaped 
lesion was detected in the left kidney (arrowheads), enabling the 
US-guided biopsy.
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status within the tumor [71-73], and the treatment response 
of the anti-angiogenic regime shows that the TTP enhancement 
increases significantly in the responder group as compared to the 
nonresponder group [74].
There are some drawbacks of a CEUS quantitative perfusion 
study. Quantitative parameters from CEUS perfusion can affect 
various conditions such as acoustic attenuation, field differences, 
US system settings, and cardiac output. Therefore, normalization of 
such quantitative parameters has been recommended to solve this 
problem [67]. Furthermore, motion correction is still not possible in 
CEUS perfusion studies; hence, the technical success rate was found 
to be lower than that of CECT (100% vs. 70%) [68]. Lastly, just as 
CEUS is used for diagnostic purposes, a quantitative analysis with 
CEUS cannot be routinely performed for deep-seated lesions or in 
patients with severe fatty liver because most of the ultrasound beam 
is scattered or reflected before reaching the targeted lesion.
Evaluation of Other Organs
For the differentiation between neoplasms and pseudotumors, such 
as the column of Bertin or the dromedary hump in the kidney, CEUS 
can be used. If the enhancement pattern is similar to the adjacent 
renal parenchyma and there is no mass effect on the renal vessel, the 
mass of interest is more likely to be a pseudotumor than an actual 
neoplasm. CEUS can also delineate lesions that are well visualized 
A B
Fig. 7. A 49-year-old male underwent renal transplantation. 
A. On contrast-enhanced ultrasonography, the hematoma (arrowheads) was well visualized around the transplanted kidney, but there was no 
evidence of active bleeding within the hematoma. B. A 2.8-cm unruptured aneurysm (arrow) was seen at the renal artery (arrowhead). C. On 
renal angiography, the renal artery aneurysm (arrow) was found to have originated from the transplanted renal artery. Stent graft placement 
was performed at the renal artery. D. After 1 week, the renal artery aneurysm was no longer visible. The arrowhead indicates the renal artery.
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on CECT but are not noted on conventional grayscale US (Fig. 6). For 
complex cystic lesions, the presence or absence of enhancing mural 
nodules and thick irregular septa can be evaluated with CEUS in 
addition to Doppler US [6]. After kidney transplantation, CEUS can 
be helpful in the evaluation of vessels and their anastomosis sites if 
CECT is not feasible due to a renal function that is not yet restored 
or stabilized (Fig. 7). In the case of pancreatic applications, CEUS 
is still used to acquire additional information after cross-sectional 
imaging, rather than for the detection or differentiation of focal 
pancreatic lesions [16]. Most pancreatic adenocarcinomas appear 
as hypovascular on CEUS, and CEUS can visualize the tumor margin 
and the relationship between a tumor and its adjacent vessels 
more clearly [75,76]. Enhanced mural nodules are very suggestive 
findings for malignant cystic pancreatic neoplasms, and CEUS can 
differentiate a mural nodule from a hematoma or a sludge ball 
[16]. CEUS can improve the visualization of the aortic lumen and an 
endoleak in patients with abdominal aortic aneurysm or dissection. 
CT angiography can also accurately detect an endoleak, but CEUS 
can provide additional information for identifying the endoleak type 
by a real-time examination (Fig. 8) [16]. Although CECT is still the 
gold standard for evaluating blunt abdominal trauma, CEUS can be 
an alternate option in patients with low-energy blunt abdominal 
trauma in which CECT does not seem mandatory but in which an 
abdominal evaluation is still needed [6]. In terms of a diffuse liver 
injury, CEUS can depict injured areas without requiring that patients 
be moved to the CT room even if conventional B mode US cannot 
detect any abnormalities in the liver [77].
Conclusion
CEUS has unique advantages over CECT and CEMR, as US contrast 
agents are safer than iodinated or gadolinium chelate contrast 
agents given that they have no effect on the kidney and thyroid 
function while having no radiation and being easily accessible. The 
A B
Fig. 8. A 58-year-old male who underwent stent graft due to 
abdominal aortic aneurysm. 
A. On contrast-enhanced computed tomography (CT), contrast agent 
extravasation (arrow) was suspected at the excluded aneurysmal 
sac. The patient had already undergone embolization therapy 
with Lipiodol and Histoacryl due to an endoleak (arrowhead). B. 
On contrast-enhanced ultrasonography, the contrast agent was 
observed in the excluded aneurysmal sac outside the aorta (arrow) 
but not from the abdominal aortic lumen, which was suggestive of 
a type-II endoleak. C. Embolization therapy was performed, and no 
evidence of a residual endoleak was found on the follow-up CT. 
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development of second-generation US contrast agents that enable 
an actual real-time study with low-MI techniques boosts the use of 
CEUS in many applications. The detection rate and the diagnostic 
accuracy of focal liver lesions can also be improved by CEUS. 
Although there is debate on whether CEUS plays a crucial role in the 
management of HCC, CEUS may improve diagnostic performance 
in patients with liver cirrhosis or chronic hepatitis. CEUS can also 
be applied to organs other than the liver; some examples of such 
applications are the detection and differentiation of kidney lesions, 
clearer delineation of pancreatic cancer and the adjacent vessels, 
evaluation of aortic or other vascular abnormalities, and the 
evaluation of blunt abdominal trauma. For patients who receive anti-
angiogenic drugs, it has the potential to be a tool complementary 
to cross-sectional imaging in the assessment of the treatment 
response, while providing additional enhancement or perfusion 
information along with size changes. In summary, CEUS exhibits 
a better diagnostic performance than conventional grayscale US 
and an accuracy similar to that of CECT or CEMR in the evaluation 
of liver and vascular diseases, although there are some limitations 
due to the physical properties of US. Having the advantages of no 
radiation exposure or no nephrotoxicity, CEUS may be more widely 
used as a first-line or problem-solving tool in the future.
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